Welcome to our dedicated page for Sigyn Therapeutics SEC filings (Ticker: SIGY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sigyn Therapeutics, Inc. filings document the reporting and capital-structure disclosures of a development-stage medical technology company. Recent records include a Rule 12b-25 notice covering the timing of an annual Form 10-K and Form 8-K disclosure of convertible note purchase agreements, including interest terms, conversion mechanics, common-stock issuance terms and Securities Act exemption language.
Sigyn Therapeutics, Inc. notified the SEC that it could not timely file its Form 10-K for the period ended December 31, 2025. The company states that compilation, dissemination and review of required information made timely filing impracticable and will file the Form 10-K no later than five days after its original due date. The notification is signed by James Joyce, Chief Executive Officer, on March 31, 2026.
Sigyn Therapeutics, Inc. entered into three one-year convertible note purchase agreements with institutional investors, raising small amounts of short-term funding through unregistered securities.
On February 12, 2026, the company issued two convertible notes: one to Brio Capital Master Fund, Ltd and one to Osher Capital Partners, LLC, each with a principal amount of $22,222.22 and providing gross proceeds of $20,000.00. On February 6, 2026, it issued a third note to Lambda Venture Partners, LLC with a principal amount of $27,777.77 and net proceeds of $21,500.00 after legal fees.
Each note bears interest at 8% per year and is convertible at the holder’s option into common stock at a price equal to a 35% discount to the lowest traded price of Sigyn’s common shares during the 20 trading days before a conversion notice. No stock purchase warrants were issued, and the issuances are described as exempt from registration under Section 4(a)(2) of the Securities Act.
Sigyn Therapeutics, Inc. received an amended Schedule 13G/A showing that Brio Capital Master Fund Ltd., together with Brio Capital Management LLC, reports beneficial ownership of 160,537 shares of common stock, representing 9.99% of the class.
The filing explains that this amount includes 84,608 shares of common stock plus additional shares issuable from warrants, convertible notes and convertible preferred shares, subject to a 9.99% beneficial ownership cap. The percentage is based on 1,605,377 shares outstanding as of November 14, 2025. The reporting persons certify the holdings are not for the purpose of changing or influencing control of the company.
Sigyn Therapeutics (SIGY) filed its Q3 2025 10‑Q, reporting continued losses and limited liquidity. The company posted a net loss of $578,503 for the quarter and $2,698,254 for the nine months ended September 30, 2025. Cash was $85,571 with total assets of $135,571, against total liabilities of $6,052,780, resulting in a stockholders’ deficit of $(5,917,209). The filing states substantial doubt about the company’s ability to continue as a going concern.
Sigyn had no revenue and funded operations through convertible debt and a Regulation D offering. In 2025 it sold 69 Units for $379,717 aggregate principal (cash received $345,197) and issued additional 2025 convertible notes, including variable‑price notes that created a $181,362 derivative liability. Key noteholders extended maturities to December 31, 2027 in exchange for original issue discounts totaling $737,786. An inducement to preferred holders resulted in a $845,901 expense.
The company is repositioning around CardioDialysis and filed a trademark to support the strategy shift. As of November 14, 2025, common shares outstanding were 1,605,377.